Synovics Pharmaceuticals Stock Forward View - Simple Exponential Smoothing
| SYVC Stock | USD 0.0001 0.00 0.00% |
This prediction module for Synovics Pharmaceuticals is designed to work alongside - not replace - fundamental and technical analysis. It adds a sentiment layer that captures how the market's story about Synovics Pharmaceuticals is currently priced.
From the most recent analysis, Synovics Pharmaceuticals reflects the short-cycle RSI of 0, indicating compressed downside momentum. Readings below 20 are commonly associated with potential stabilization zones.Momentum
Sell Peaked
Oversold | Overbought |
Quarterly Revenue Growth -0.80 |
This view maps Synovics Pharmaceuticals attention shifts to recent price behavior and peer activity.
The Simple Exponential Smoothing forecasted value of Synovics Pharmaceuticals on the next trading day is expected to be 0.0001 with a mean absolute deviation of 0.00 and the sum of the absolute errors of 0.00.Synovics Pharmaceuticals after-hype prediction price | $ 1.0E-4 |
The hype panel supports comparisons with forecasting models, technical signals, analyst consensus, and earnings.
Historical Fundamental Analysis of Synovics Pharmaceuticals provides a cross-check on projections for Synovics Pharmaceuticals. The historical series provides projection context.Synovics Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Synovics price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Synovics using various technical indicators. When you analyze Synovics charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Synovics Pharmaceuticals Simple Exponential Smoothing Price Forecast For the 12th of March 2026
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of Synovics Pharmaceuticals on the next trading day is expected to be 0.0001 with a mean absolute deviation of 0.00, mean absolute percentage error of 0.00, and the sum of the absolute errors of 0.00.Please note that although there have been many attempts to predict Synovics Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Synovics Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Synovics Pharmaceuticals Stock Forecast Pattern
| Backtest Synovics Pharmaceuticals | Synovics Pharmaceuticals Price Prediction | Research Analysis |
Synovics Pharmaceuticals Forecasted Value
This next-day forecast for Synovics Pharmaceuticals uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Synovics Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent Synovics Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | -9.223372036854776E14 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0 |
| MAPE | Mean absolute percentage error | 0.0 |
| SAE | Sum of the absolute errors | 0.0 |
Valuation-driven investors use mean reversion to time Synovics Pharmaceuticals' investments: buying when it trades materially below its historical average valuation multiples and selling when it reaches premium territory.
Synovics Pharmaceuticals After-Hype Price Density Analysis
The price distribution chart for Synovics Pharmaceuticals visualizes our statistical uncertainty about Synovics Pharmaceuticals' future price. This uncertainty is inherent in all forecasting, and any model claiming to eliminate it for Synovics Pharmaceuticals should be viewed with skepticism.
Next price density |
| Expected price to next headline |
Synovics Pharmaceuticals Estimiated After-Hype Price Volatility
Our news impact model for Synovics Pharmaceuticals estimates the statistical distribution of after-hype price outcomes based on Synovics Pharmaceuticals' historical reactions to comparable events. Synovics Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.00 and 0.00, respectively. The model is descriptive rather than predictive and reflects what has historically happened - not what will.
Current Value
The after-hype framework applied to Synovics Pharmaceuticals assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Synovics Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Synovics Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Synovics Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Synovics Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 1 Events | 0 Events | Very soon |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.0001 | 0.0001 | 0.00 |
|
Synovics Pharmaceuticals Hype Timeline
Synovics Pharmaceuticals is at this time traded for 0.0001. The company stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Synovics is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is at this time at 0.0%. %. The volatility of related hype on Synovics Pharmaceuticals is about 0.0%, with the expected price after the next announcement by competition of 0.00. The company had not issued any dividends in recent years. Synovics Pharmaceuticals completed a 1:5 stock split on 30th of May 2001. Given the investment horizon of 90 days the next anticipated press release will be very soon. Historical Fundamental Analysis of Synovics Pharmaceuticals provides a cross-check on projections for Synovics Pharmaceuticals. The historical series provides projection context.Synovics Pharmaceuticals Related Hype Analysis
The peer hype summary table for Synovics Pharmaceuticals serves as a competitive intelligence tool, helping investors understand the news sensitivity landscape around Synovics Pharmaceuticals' sector and identify the companies most likely to influence Synovics Pharmaceuticals's near-term performance.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CMRA | Comera Life Sciences | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SNNAQ | Sienna Biopharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| GBIM | GlobeImmune | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RBSH | Rebus Holdings | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NLVVF | New Leaf Ventures | 0.00 | 1 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NTII | Neurobiological Technologies | 0.00 | 1 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ANTH | Anthera Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| COTQF | Cotinga Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| TNGNQ | Tengion | 0.00 | 4 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FPMI | Fluoropharma Medical | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Forecasting Options for Synovics Pharmaceuticals
Price movement is the most critical factor for any investor assessing the potential of Synovics as an investment. The noise inherent in Synovics Stock price charts can obscure the underlying direction and make investment decisions more challenging.Synovics Pharmaceuticals Related Equities
The following equities are related to Synovics Pharmaceuticals within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Synovics Pharmaceuticals against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Synovics Pharmaceuticals Market Strength Events
For investors in Synovics Pharmaceuticals, market strength indicators provide essential context about how the stock responds to prevailing market trends. These tools support more informed decisions about when to trade Synovics Pharmaceuticals for maximum effect.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
Story Coverage note for Synovics Pharmaceuticals
Coverage intensity for Synovics Pharmaceuticals matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Other Macroaxis Stories
Story coverage on Macroaxis is built for readers who approach markets from different levels of experience but share the same need for disciplined investment context. Used well, these stories become part of a broader workflow built around idea generation, validation, and risk-adjusted portfolio design.
Story Categories
Currently Trending Categories
More Resources for Synovics Stock Analysis
A structured review of Synovics Pharmaceuticals often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Key reports that frame Synovics Pharmaceuticals Stock are listed below:Historical Fundamental Analysis of Synovics Pharmaceuticals provides a cross-check on projections for Synovics Pharmaceuticals. The historical series provides projection context. Get started with Synovics Stock investing by reading our How to Invest in Synovics Stock guide.Analysis related to Synovics Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Investors evaluate Synovics Pharmaceuticals using market value and book value, each describing different facets of the business. Synovics Pharmaceuticals' market capitalization is 542.86 K. Enterprise value stands at 894.82 K. Intrinsic value is an analytical estimate of Synovics Pharmaceuticals' underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
Value and price for Synovics Pharmaceuticals are related but not identical, and they can diverge across cycles. For Synovics Pharmaceuticals, key inputs include a profit margin of -26.42%, ROE of -3.14%, and revenue of 25.96 M. Trading price represents the transaction level agreed by market participants.